{"doi":"10.1136/openhrt-2023-002489","title":"BNP level predicts bleeding event in patients with heart failure after percutaneous coronary intervention","abstract":"<jats:sec>\n                  <jats:title>Objective</jats:title>\n                  <jats:p>This study aimed to investigate the association between heart failure (HF) severity measured based on brain natriuretic peptide (BNP) levels and future bleeding events after percutaneous coronary intervention (PCI).</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>The Academic Research Consortium for High Bleeding Risk presents a bleeding risk assessment for antithrombotic therapy in patients after PCI. HF is a risk factor for bleeding in Japanese patients.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>Using an electronic medical record-based database with seven tertiary hospitals in Japan, this retrospective study included 7160 patients who underwent PCI between April 2014 and March 2020 and who completed a 3-year follow-up and were divided into three groups: no HF, HF with high BNP level and HF with low BNP level. The primary outcome was bleeding events according to the Global Use of Streptokinase and t-PA for Occluded Coronary Arteries classification of moderate and severe bleeding. The secondary outcome was major adverse cardiovascular events (MACE). Furthermore, thrombogenicity was measured using the Total Thrombus-Formation Analysis System (T-TAS) in 536 consecutive patients undergoing PCI between August 2013 and March 2017 at Kumamoto University Hospital.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>Multivariate Cox regression showed that HF with high BNP level was significantly associated with bleeding events, MACE and all-cause death. In the T-TAS measurement, the thrombogenicity was lower in patients with HF with high BNP levels than in those without HF and with HF with low BNP levels.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions</jats:title>\n                  <jats:p>HF with high BNP level is associated with future bleeding events, suggesting that bleeding risk might differ depending on HF severity.</jats:p>\n               </jats:sec>","journal":"Open Heart","year":2023,"id":644924,"datarank":0.37273599746820013,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"self_citation_contribution":0.37273599746820013,"citation_network_contribution":0.0,"self_endowment_contribution":0.37273599746820013,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1678947,"name":"Masanobu Ishii","orcid":"0000-0003-4137-9136","position":1,"is_corresponding":false},{"id":1678948,"name":"So Ikebe","orcid":null,"position":2,"is_corresponding":false},{"id":1678949,"name":"Taishi Nakamura","orcid":null,"position":3,"is_corresponding":false},{"id":1014506,"name":"Kenichi Tsujita","orcid":"0000-0002-4314-259X","position":4,"is_corresponding":false},{"id":1678950,"name":"Koichi Kaikita","orcid":null,"position":5,"is_corresponding":false},{"id":1678951,"name":"Tetsuya Matoba","orcid":null,"position":6,"is_corresponding":false},{"id":938085,"name":"Takahide Kohro","orcid":"0000-0002-8400-4177","position":7,"is_corresponding":false},{"id":1678954,"name":"Yusuke Oba","orcid":null,"position":8,"is_corresponding":false},{"id":1628019,"name":"Tomoyuki Kabutoya","orcid":"0000-0002-5439-4303","position":9,"is_corresponding":false},{"id":458581,"name":"Kazuomi Kario","orcid":"0000-0002-8251-4480","position":10,"is_corresponding":false},{"id":1678959,"name":"Yasushi Imai","orcid":null,"position":11,"is_corresponding":false},{"id":1678961,"name":"Arihiro Kiyosue","orcid":null,"position":12,"is_corresponding":false},{"id":1678962,"name":"Yoshiko Mizuno","orcid":null,"position":13,"is_corresponding":false},{"id":1645548,"name":"Kotaro Nochioka","orcid":"0000-0001-8297-8624","position":14,"is_corresponding":false},{"id":111696,"name":"Masaharu Nakayama","orcid":null,"position":15,"is_corresponding":false},{"id":1678963,"name":"Takamasa Iwai","orcid":null,"position":16,"is_corresponding":false},{"id":700587,"name":"Yoshihiro Miyamoto","orcid":"0000-0002-1337-0508","position":17,"is_corresponding":false},{"id":1678964,"name":"Hisahiko Sato","orcid":null,"position":18,"is_corresponding":false},{"id":1678965,"name":"Naoyuki Akashi","orcid":"0000-0002-8603-2630","position":19,"is_corresponding":false},{"id":1508356,"name":"Hideo Fujita","orcid":null,"position":20,"is_corresponding":false},{"id":11202,"name":"Ryozo Nagai","orcid":"0000-0002-0911-7868","position":21,"is_corresponding":false},{"id":1678946,"name":"Yasuhiro Otsuka","orcid":"0009-0006-6424-2537","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"BNP level predicts bleeding event in patients with heart failure after percutaneous coronary intervention","abstract":"<jats:sec>\n                  <jats:title>Objective</jats:title>\n                  <jats:p>This study aimed to investigate the association between heart failure (HF) severity measured based on brain natriuretic peptide (BNP) levels and future bleeding events after percutaneous coronary intervention (PCI).</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>The Academic Research Consortium for High Bleeding Risk presents a bleeding risk assessment for antithrombotic therapy in patients after PCI. HF is a risk factor for bleeding in Japanese patients.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>Using an electronic medical record-based database with seven tertiary hospitals in Japan, this retrospective study included 7160 patients who underwent PCI between April 2014 and March 2020 and who completed a 3-year follow-up and were divided into three groups: no HF, HF with high BNP level and HF with low BNP level. The primary outcome was bleeding events according to the Global Use of Streptokinase and t-PA for Occluded Coronary Arteries classification of moderate and severe bleeding. The secondary outcome was major adverse cardiovascular events (MACE). Furthermore, thrombogenicity was measured using the Total Thrombus-Formation Analysis System (T-TAS) in 536 consecutive patients undergoing PCI between August 2013 and March 2017 at Kumamoto University Hospital.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>Multivariate Cox regression showed that HF with high BNP level was significantly associated with bleeding events, MACE and all-cause death. In the T-TAS measurement, the thrombogenicity was lower in patients with HF with high BNP levels than in those without HF and with HF with low BNP levels.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions</jats:title>\n                  <jats:p>HF with high BNP level is associated with future bleeding events, suggesting that bleeding risk might differ depending on HF severity.</jats:p>\n               </jats:sec>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38065584","pmcid":"PMC10711837","openalex_id":null,"authors":[],"funders":[{"funder_name":"Health Labour Sciences Research Grant","grant_id":"22FA1016","title":null},{"funder_name":"programs for Progress of the next Cross-ministerial Starategic Innovation Promotion Program (SIP) on '' Integrated Health Care System''","grant_id":"JPJ012425","title":null},{"funder_name":"Kowa Company, Ltd.","grant_id":"","title":null},{"funder_name":"Kowa Company","grant_id":"","title":null}],"total_grants":4,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":null,"license":"http://creativecommons.org/licenses/by-nc/4.0/","oa_locations":[{"url":"https://syndication.highwire.org/content/doi/10.1136/openhrt-2023-002489","host_type":"publisher"},{"url":"https://openheart.bmj.com/content/openhrt/10/2/e002489.full.pdf","host_type":"Unpaywall"},{"url":"https://europepmc.org/articles/PMC10711837","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC10711837?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":[],"mesh_terms":["Humans","Hemorrhage","Natriuretic Peptide, Brain","Risk Factors","Retrospective Studies","Heart Failure","Percutaneous Coronary Intervention"],"keywords":["Biomarkers","Percutaneous coronary intervention","Heart Failure"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-09T02:27:27.105133Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}